Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.35 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656727 | 0.78 | HDAC1 (0.41) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL198643 | 0.77 | GRAMD1A (0.53) | HDAC1 | |
| SCHEMBL196952 | 0.74 | HDAC1 (0.44) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL199351 | 0.73 | HDAC2 (0.47) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL197818 | 0.72 | F10 (0.49) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL197046 | 0.71 | HDAC1 (0.46) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL197315 | 0.71 | GRM5 (0.46) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL197962 | 0.70 | KMT2A (0.45) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL658230 | 0.70 | HDAC1 (0.39) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL1920006 | 0.69 | HDAC1 (0.41) | HDAC1HDAC3HDAC2HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885HDAC3 4/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.